13551-002 NDC - LUMRYZ (SODIUM OXYBATE)

Drug Information

Product NDC: 13551-002

Proprietary Name: Lumryz

Non Proprietary Name: sodium oxybate

Active Ingredient(s):
  • 6 g/1 SODIUM OXYBATE


Administration Route(s): ORAL

Dosage Form(s): FOR SUSPENSION, EXTENDED RELEASE

Pharmacy Class(es):
  • Central Nervous System Depressant [EPC];
  • Central Nervous System Depression [PE];
  • Decreased Central Nervous System Organized Electrical Activity [PE]

Labeler Information

Labeler Name: Avadel CNS Pharmaceuticals, LLC
Product Type: HUMAN PRESCRIPTION DRUG
FDA Application Number: NDA214755
Marketing Category: NDA
Start Marketing Date:5/1/2023
DEA Schedule:CIII

Package Information

No. Package Code Package Description Billing Unit
113551-002-077 PACKET in 1 CARTON (13551-002-07) / 1 FOR SUSPENSION, EXTENDED RELEASE in 1 PACKET (13551-002-00)
213551-002-3030 PACKET in 1 CARTON (13551-002-30) / 1 FOR SUSPENSION, EXTENDED RELEASE in 1 PACKET (13551-002-00)

NDC Record

Field Name Field Value Definition
PRODUCT NDC13551-002The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
PRODUCT TYPE NAMEHUMAN PRESCRIPTION DRUGIndicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
PROPRIETARY NAMELumryzThe proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.
NON PROPRIETARY NAMEsodium oxybateThe non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
DOSAGE FORM NAMEFOR SUSPENSION, EXTENDED RELEASEThe translation of the dosage form Code submitted by the firm.
ROUTE NAMEORALThe translation of the route code submitted by the firm, indicating route of administration.
START MARKETING DATE5/1/2023This is the date that the labeler indicates was the start of its marketing of the drug product.
MARKETING CATEGORY NAMENDAProduct types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
APPLICATION NUMBERNDA214755This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
LABELER NAMEAvadel CNS Pharmaceuticals, LLCName of Company corresponding to the labeler code segment of the Product NDC.
SUBSTANCE NAMESODIUM OXYBATEAn active ingredient is the substance responsible for the medicinal effects of a product specified by the substance's molecular structure or if the molecular structure is not known, defined by an unambiguous definition that identifies the substance. Each active ingredient name is the preferred term of the UNII code submitted.
ACTIVE NUMERATOR STRENGTH6 
ACTIVE INGRED UNITg/1 
PHARM CLASSESCentral Nervous System Depressant [EPC], Central Nervous System Depression [PE], Decreased Central Nervous System Organized Electrical Activity [PE] 
DEA SCHEDULECIIIThis is the assigned DEA Schedule number as reported by the labeler. Values are CI, CII, CIII, CIV, and CV.

Download Record

Download this NDC record in Text format: Export

Download this NDC record in Excel (CSV) format: Export

Download this NDC record in XML format: Export

This page was last updated on: 5/26/2023